• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 07-May-2021 EOD, Market Closed
SENSEX
49,206.47
256.71 (0.52%)
NIFTY
14,823.15
98.35 (0.67%)
    No Companies Visited

Back to news list
  • Alembic Pharma gains after Q4 PAT rises 12% to Rs 251 cr

    Alembic Pharmaceuticals rose 1.67% to Rs 999.40 after the company's consolidated net profit jumped 12% to Rs 251 crore on 6% increase in net sales to Rs 1,280 crore in Q4 FY21 over Q4 FY20.

    On a consolidated basis, the company's net profit jumped 42% to Rs 1178 crore on 17% increase in net sales to Rs 5393 crore in the year ended March 2021 over the year ended March 2020.

    International formulations jumped 19% Y-o-Y (year-on-year) to Rs 2,942 crore in FY21 over FY20. US Generics spurted 9% Y-o-Y to Rs 2,163 crore in FY21 over FY20. Ex-US International Formulations soared 57% Y-o-Y to Rs 779 crore in FY21.

    13 ANDA's were filed in the quarter and 29 ANDA filings for the year. Research & Department (R&D) spend was reported at 12% of revenue or Rs 670 crore for the year.

    India branded formulations business grew 5% to Rs 1,497 crore in FY21 from FY20. API business grew 38% Y-o-Y to Rs 214 crore in the quarter and 35% Y-o-Y to Rs 955 crore in FY21 over FY20. Two Drug Master File (DMF) were filed in the quarter while the cumulative DMF fillings stood at 117.

    Pranav Amin, the managing director of Alembic Pharmaceuticals, said: "It was an outstanding year with the company recording its highest sales and profit ever. This was led by strong growth in the API and International Business. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted."

    The board has recommended a dividend of Rs 14 per share.

    Meanwhile, Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1%.

    The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel Gel, 1 %, of Galderma Laboratories LP (Galderma). The product is indicated for Indicated for the topical treatment of inflammatory lesions of rosacea.

    Metronidazole Gel USP, 1% has an estimated market size of $32 million for twelve months ending December 2020 according to IQVIA.

    Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
91-22-25230011
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 07-May-2021
  •  ( 15:45) European markets trade higher  
  •  ( 15:43) Metal stocks shine  
  •  ( 15:43) Sensex rises 256 pts on positive global signals  
  •  ( 14:32) Sensex, Nifty trade range bound with gains  
  •  ( 13:46) The Nifty index continues to hover below 14,800; Asian markets trade mixed  
  •  ( 13:45) Indices trade range bound; positive market breadth  
  •  ( 12:59) LIC of India hikes 2.03% stake in IRB Infrastructure Developers  
  •  ( 12:42) RailTel Corp. bags order win worth Rs 11.99 cr from Cotton Corp.  
  •  ( 12:32) Metal stocks shine  
  •  ( 12:32) Market breadth positive  
  •  ( 12:31) Indices pare gains  
  •  ( 12:31) Praj Industries consol. Q4 FY21 PAT up 109.2% Y-o-Y to Rs 52.01 cr  
  •  ( 11:57) Raymond consol. Q4 FY21 PAT stands at Rs 58.36 cr  
  •  ( 11:27) Procter & Gamble Health Q3 FY21 PAT down 66.1% Y-o-Y to Rs 15.77 cr  
  •  ( 11:27) Procter & Gamble Health Q4 FY21 PAT down 66.1% Y-o-Y to Rs 15.77 cr  
  •  ( 11:02) Blue Star records PAT of Rs 67.97 crore in Q4 FY21 vs Rs 8.90 crore in Q4 FY20  
  •  ( 10:57) Adani Transmission consol. Q4 FY21 PAT up 335.1% Y-o-Y to Rs 256.55 cr  
  •  ( 10:31) Market breadth positive  
  •  ( 10:30) Indices trade sideways with gains  
  •  ( 10:02) Adani Power consol. Q4 FY21 PAT stands at Rs 13.13 cr  
  •  ( 09:37) Cupid receives order from Uttar Pradesh Medical Supplies Corporation for Rs 10.5 cr  
  •  ( 09:32) Hero MotoCorp Q4 PAT up over 39% YoY to Rs 865 crore  
  •  ( 09:29) Sensex moves above 49,000; breadth strong   
  •  ( 09:25) UK-based Infinity Circle selects Zensar Technologies to manage wealth biz.  
  •  ( 08:09) Asian stocks advance as investors look ahead to U.S. jobs report  
Show News
07 May 2021 00:00
2551.50
(0.10 %)
716.75
(0.13 %)
3867.10
(-1.94 %)
5491.05
(-0.69 %)
11315.60
(2.59 %)
568.50
(1.82 %)
5173.55
(0.15 %)
2496.25
(2.70 %)
916.25
(0.06 %)
1414.60
(0.94 %)
2413.00
(1.00 %)
606.75
(-0.31 %)
925.60
(0.07 %)
1352.40
(-0.64 %)
205.35
(1.28 %)
1779.95
(-0.39 %)
1342.90
(0.23 %)
767.15
(2.68 %)
6702.90
(0.56 %)
16753.55
(0.16 %)
105.05
(2.04 %)
111.50
(1.27 %)
214.60
(-0.37 %)
1931.30
(0.07 %)
358.20
(0.76 %)
679.50
(0.04 %)
3132.00
(0.67 %)
980.80
(0.31 %)
1448.70
(0.36 %)
6484.80
(1.23 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.